Trial Profile

An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients ≥6 Months to <18 Years of Age With Atopic Dermatitis

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 30 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

07 Jun 2024 Planned End Date changed from 19 Aug 2026 to 7 Oct 2026.
07 Jun 2024 Planned primary completion date changed from 19 Aug 2026 to 7 Oct 2026.
12 Mar 2024 Results (n=763) assessing the proportion of pediatric patients achieving EASI <7 (mild disease activity) across 5 visits during 52-week presented at the American Academy of Dermatology annual Meeting 2024

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com